Evotec and QIAGEN enter software collaboration for enhanced multi-omics data insights

• Collaboration leverages synergies of QIAGEN’s OmicSoft omics data through Evotec’s analysis platform PanHunter
• Customers accelerate target discovery decisions with high-quality multi-omic evidence, and expanded analysis capabilities

Hamburg, Germany, and Venlo, the Netherlands, 03 June 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a collaboration to leverage QIAGEN’s OmicSoft Land Databases through Evotec’s PanOmics data access and analysis platform PanHunter. Combining comprehensive data sets with advanced analytics capabilities will enable enhanced multi-omics data insights, better disease understanding and more precise therapeutic interventions.

Omics data offers extensive insights into patient conditions, molecular biology, and disease causes. QIAGEN’s market-leading OmicSoft solution accelerates research discoveries in biotech and pharma with vast amounts of annotated Omics data. QIAGEN’s OmicSoft Land Databases comprise integrated collections of multi-omics data and metadata, so-called “Lands”, which have been curated and standardised from the largest public dataset repositories. Through these deeply-curated and unified datasets, data scientists avoid common pitfalls of data mining, and can focus on powerful target profiling and indication expansion efforts.

PanHunter is Evotec’s interactive, collaborative, and easy-to-use analysis software for biological data. The next-generation platform combines published and peer-reviewed or in-house developed statistical analysis algorithms with AI/ML capabilities and enables in-depth analysis across PanOmics data sets. PanHunter offers researchers the flexibility to examine a few entries or correlate millions of data points, while also enhancing insights by associating meta-information, reference data and chemical and structural information for compounds, and clinical data.

The collaboration provides QIAGEN’s and Evotec’s partners and clients with an option to integrate licensed data from OmicSoft Lands with other data sets and perform comprehensive data analysis through PanHunter, thus enhancing the functionality and value of both platforms.

Dr Matthias Evers, Chief Business Officer of Evotec, commented: “We are excited about the partnership with QIAGEN as it is a testament to both our companies’ commitment to empowering users with unparalleled data analysis capabilities. By seamlessly integrating our strengths, we are not only connecting software, but revolutionising how scientists harness the power of data.”

Jonathan Sheldon, EVP Digital Insights at QIAGEN, said: “We believe this partnership will enable our shared customers to realise the promise of better insights and faster outcomes through AI and machine learning, by using the combination of the world’s leading Omics database with Evotec’s unique platform.”

For further information, please follow this link to the PanHunter website or contact us via panhunter@evotec.com.